EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Romosozumab is effective in patients with variants in LRP5, LRP6, or WNT1

Felix N von Brackel, Nicolas Dehne, Uwe Kornak, Florian Barvencik, Thorsten Schinke, Michael Amling, Ralf Oheim

Osteoporosis International · 2026

DOI: 10.1007/s00198-026-07932-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Osteoporosis International, 2026. Verfasst von Felix N von Brackel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department for Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Lottestrasse 59, Hamburg, Germany. Hauptthemen laut MEDLINE: Bone Density Conservation Agents, Osteoporosis, Postmenopausal, Antibodies, Monoclonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, UCB Pharma Germany, Universitätsklinikum Hamburg-Eppendorf (UKE).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Romosozumab has proven efficacy in postmenopausal osteoporosis, but data in LRP5/6 or WNT1 variant carriers are scarce. In 33 patient-years of women carrying such variants, romosozumab improved BMD and bone formation more than antiresorptives or no treatment. These findings suggest romosozumab as a potential therapy for genetically defined bone loss. PURPOSE: The sclerostin inhibitor romosozumab is an osteoanabolic drug that enhances the canonical Wnt-β-catenin pathway. While its efficacy in postmenopausal osteoporosis is known, clinical data on the use of romosozumab in patients with variants in the LRP5, LRP6, or WNT1 gene affecting this pathway remain limited. METHOD: We present clinical routine data of 33 patient-years in 27 postmenopausal women with heterozygous deleterious or established risk alleles variants (ACMG class 2-5) in the LRP5/6 or WNT1 gene, using dual-energy X-ray absorptiometry (DXA), high-resolution peripheral quantitative computed tomography (HR-pQCT), and laboratory parameters. Among these, 12 were treated with vitamin D and calcium only (NoT), 11 with antiresorptive therapy (AR), and 10 with romosozumab (ROMO). RESULTS: Patients treated with romosozumab showed significantly greater gains in areal bone mineral density (aBMD) compared to others (lumbar spine-NoT = -0.12% ± 5.02%, AR = + 3.97% ± 4.71%, ROMO = + 15.74% ± 7.63%, p < 0.001 for ROMO vs. AR and vs. NoT). This was accompanied by an increase in trabecular bone density and mass in the tibia, as well as elevated bone formation markers such as bone alkaline phosphatase after 6 months (AR = -3.36 µg/L ± 8.044 µg/L vs. ROMO = + 3.08 µg/L ± 2.21 µg/L, p = 0.026). Our findings indicate that romosozumab is effective in patients with heterozygous variants in the LRP5/6 or WNT1 gene. Here, romosozumab was superior to established antiresorptive treatments. CONCLUSION: Thus, romosozumab might be a specific treatment for these patients. However, further studies are needed with larger patient cohorts and in particular with regard to biallelic loss-of-function variants in the LRP 5/6 or WNT1 gene.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone Density Conservation AgentsOsteoporosis, PostmenopausalAntibodies, MonoclonalHumansFemaleLow Density Lipoprotein Receptor-Related Protein-5Bone DensityWnt1 ProteinMiddle AgedAgedLow Density Lipoprotein Receptor-Related Protein-6Absorptiometry, PhotonLumbar Vertebrae

Stichwörter der Autor:innen

HR-pQCTLRP5OsteoporosisRomosozumabWnt-Signalig

Substanzen

Low Density Lipoprotein Receptor-Related Protein-5Wnt1 ProteinLRP5 protein, humanromosozumabBone Density Conservation AgentsAntibodies, MonoclonalLow Density Lipoprotein Receptor-Related Protein-6LRP6 protein, humanWNT1 protein, human

Autor:innen und Institutionen

  • Department for Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Lottestrasse 59, Hamburg, Germany.
  • Institute of Human Genetics, University Medical Center Göttingen, Göttingen, 37073, Germany.
  • Department for Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Lottestrasse 59, Hamburg, Germany. r.oheim@uke.de.

Förderung

  • Deutsche Forschungsgemeinschaft
  • UCB Pharma Germany
  • Universitätsklinikum Hamburg-Eppendorf (UKE)

Zitieren

APA

von Brackel, F. N., Dehne, N., Kornak, U., Barvencik, F., Schinke, T., Amling, M., & Oheim, R. (2026). Romosozumab is effective in patients with variants in LRP5, LRP6, or WNT1. Osteoporosis International. https://doi.org/10.1007/s00198-026-07932-8

Vancouver

von Brackel FN, Dehne N, Kornak U, Barvencik F, Schinke T, Amling M, et al. Romosozumab is effective in patients with variants in LRP5, LRP6, or WNT1. Osteoporosis International. 2026. doi:10.1007/s00198-026-07932-8

BibTeX
@article{vonBrackel2026,
  author = {von Brackel, Felix N and Dehne, Nicolas and Kornak, Uwe and Barvencik, Florian and Schinke, Thorsten and Amling, Michael and Oheim, Ralf},
  title = {Romosozumab is effective in patients with variants in LRP5, LRP6, or WNT1},
  journal = {Osteoporosis International},
  year = {2026},
  doi = {10.1007/s00198-026-07932-8}
}
Kostenlos starten →